James Investment Research’s DexCom DXCM Stock Holding History

James Investment Research’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-239	Closed	-$27K	–	593
2022 Q4	$27K	Buy	+239	New	+$26.2K	﹤0.01%	419

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

James Investment Research's DXCM Position: Q1 2023 in Review

James Investment Research sold out of DexCom (DXCM) in Q1 2023, closing a stake of 239 shares — an estimated $27K sold.

James Investment Research first reported a position in DXCM in Q4 2022 and held it in 1 quarter. The position peaked at $27K in Q4 2022. 904 funds tracked by Wall St. Rank hold DXCM as of Q1 2023.

James Investment Research reported no remaining DexCom position as of Q1 2023 after selling out during the quarter.
James Investment Research sold 239 DexCom shares in Q1 2023, an estimated $27K.
James Investment Research first reported a position in DexCom in Q4 2022 and held it in 1 quarter.
James Investment Research's DexCom position peaked at $27K in Q4 2022.
904 funds tracked by Wall St. Rank held DexCom as of Q1 2023.

Based on James Investment Research's 13F filing for Q1 2023, filed 26 Apr 2023.